← Back to Search

DNA Methylation Modifier

Exercise Training for Vascular Dysfunction in Obesity

N/A
Recruiting
Led By Abeer Mohamed, MD, PhD
Research Sponsored by University of Illinois at Chicago
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Between ages 18-50 years
Approved for a bariatric surgery
Must not have
Individuals with current cancer, heart, kidney or liver disease, gallbladder disease or acute or chronic inflammatory diseases (including rheumatoid arthritis, lupus and other autoimmune diseases and genetic diseases)
Timeline
Screening 3 weeks
Treatment Varies
Follow Up month 24-30
Awards & highlights

Summary

This trial is testing if reducing inflammation through exercise can help improve vascular function in obese people.

Who is the study for?
This trial is for adults aged 18-50 with severe obesity (BMI ≥ 35 kg/m2) who are approved for bariatric surgery but not currently pregnant. It excludes those with cancer, heart, kidney or liver diseases, gallbladder disease, inflammatory/autoimmune conditions, smokers, and substance abusers.Check my eligibility
What is being tested?
The study investigates if aerobic exercise can improve blood vessel function and reduce inflammation in obese individuals by altering DNA methylation—a process affecting gene activity without changing the DNA sequence itself.See study design
What are the potential side effects?
While specific side effects are not listed for exercise training interventions in this context, typical risks may include muscle soreness, fatigue, joint pain or injury. The intensity of these side effects varies from person to person.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I am between 18 and 50 years old.
Select...
I am approved for weight loss surgery.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:
Select...
I have a current diagnosis of cancer, heart, kidney, liver, gallbladder disease, or an inflammatory/autoimmune condition.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~month 24-30
This trial's timeline: 3 weeks for screening, Varies for treatment, and month 24-30 for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
DNA methylation status of adipocytokines in obese individuals
Secondary outcome measures
Flow induced dilation
Vascular health biomarkers in obese individuals before and after exercise training

Trial Design

2Treatment groups
Active Control
Group I: ExercisingActive Control1 Intervention
12 weeks of aerobic exercise training
Group II: Non-exercisingActive Control1 Intervention
standard of care

Find a Location

Who is running the clinical trial?

University of Illinois at ChicagoLead Sponsor
618 Previous Clinical Trials
1,563,958 Total Patients Enrolled
33 Trials studying Obesity
9,693 Patients Enrolled for Obesity
National Heart, Lung, and Blood Institute (NHLBI)NIH
3,854 Previous Clinical Trials
47,817,792 Total Patients Enrolled
251 Trials studying Obesity
205,811 Patients Enrolled for Obesity
Abeer Mohamed, MD, PhDPrincipal InvestigatorUniversity of Illinois at Chicago

Media Library

Exercise training (DNA Methylation Modifier) Clinical Trial Eligibility Overview. Trial Name: NCT03527420 — N/A
Obesity Research Study Groups: Exercising, Non-exercising
Obesity Clinical Trial 2023: Exercise training Highlights & Side Effects. Trial Name: NCT03527420 — N/A
Exercise training (DNA Methylation Modifier) 2023 Treatment Timeline for Medical Study. Trial Name: NCT03527420 — N/A
~14 spots leftby Jul 2025